Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Kanitra

Vascular Surgery Ypsilanti, MI Medical Doctor

NPI 1730676362 CMS profile 4449987

5325 Elliott Dr Ste 101, Ypsilanti, MI 48197

Open in the dashboard

General payments

$16,822

142 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Kanitra of Ypsilanti, MI is reported in the CMS Open Payments database as having received $16,822 across 142 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,836 39
2024 General $7,044 61
2023 General $5,986 33
2022 General $149 3
2019 General $806 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Kanitra
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to John Kanitra were reported at $2,836. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year John Kanitra Vascular Surgery median Middle half National median
2019 $806 $796 $226–$2,363 $163
2020 $0 $348 $118–$1,110 $114
2021 $0 $471 $158–$1,421 $132
2022 $149 $725 $222–$2,183 $149
2023 $5,986 $836 $257–$2,440 $160
2024 $7,044 $909 $252–$2,619 $164
2025 $2,836 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $7,886 18 payments
  2. W. L. Gore & Associates, Inc. $5,168 65 payments
  3. Bolton Medical Inc $1,262 28 payments
  4. Intuitive Surgical, Inc. $806 6 payments
  5. Silk Road Medical, Inc. $483 5 payments
  6. Penumbra, Inc. $422 5 payments
  7. Terumo Medical Corporation $333 9 payments
  8. Endologix, Inc. $308 2 payments
  9. Stryker Corporation $47 1 payment
  10. Baylis Medical Technologies Inc. $46 1 payment
  11. Other $62 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,687 127 payments
  2. Grant $5,500 2 payments
  3. Education $2,916 10 payments
  4. Travel and Lodging $719 3 payments
Products named General payments · program years 2019–2025
  1. ENDURANT IIS $7,626 17 payments
  2. EXCLUDER Conformable AAA Endoprosthesis with Active Control $1,537 20 payments
  3. TREO ABDOMINAL STENT-GRAFT SYSTEM $1,262 28 payments
  4. Da Vinci Surgical System $806 6 payments
  5. GORE VIABAHN VBX Balloon Expandable Endo $731 19 payments
  6. GORE TAG Conformable Thoracic Endoprosthesis $655 7 payments
  7. GORE VIABAHN Endoprosthesis with Heparin $487 4 payments
  8. ENROUTE Transcarotid Stent $483 5 payments
  9. ENROUTE Transcarotid Neuroprotection System $483 5 payments
  10. GORE VIABAHN Endoprosthesis $481 4 payments
  11. Other $2,919 33 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

38

Median for Surgery: 21

Drug cost

$201

Median for Surgery: $160

Branded share of claims

31.6%

Median for Surgery: 50%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 12 $157
Tramadol Hcl Generic 26 $44

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 200 Part D prescribers listed as Surgery; they describe a distribution and say nothing about conduct.

Records

142 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record